Why the study?
Does metabolomic fingerprinting predict response to cardiac resynchronization therapy in patients with heart failure?
Does metabolomic fingerprinting predict response to cardiac resynchronization therapy in patients with heart failure?
Metabolomic profiling can identify a specific fingerprint in HF patients eligible for CRT, but it does not predict their clinical response to the therapy.
Answers are grounded in this paper and cite their sources.
Metabolomic fingerprinting should not guide CRT selection in HF; hypothesis-generating and requires prospective validation.
It is possible to identify a metabolomic fingerprint characterizing heart failure patients candidate to CRT, it is independent of the different causes of the disease and it is not predictive of the response to CRT.
No takes yet. Share an insight, caveat, or question.
Padeletti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: